Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 10,857

Document Document Title
WO/2008/153159A1
It is intended to provide a novel amine compound represented by the following general formula (I), a pharmaceutically acceptable acid addition salt thereof, a hydrate thereof or a solvate thereof, which has an excellent peripheral blood ...  
WO/2008/110308A3
Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.  
WO/2008/151211A1
The present invention relates to A compound of the formula Ia wherein in any of its stereoisomers forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as desc...  
WO/2008/148468A1
The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compou...  
WO/2008/149141A2
The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(-)-2-benzhydrylsulfinylacetamide and S-(+)-2- benzhydrylsulfinylacetamide respectively.  
WO/2008/143338A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C3-C10 alkenyl group optionally substituted with at least one halogen atom...  
WO/2008/143333A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods which is represented by formula (I): wherein R1 represents a C3-C6 haloalkyl group having at least one fluorine atom and at least o...  
WO/2008/143332A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C1-C5 haloalkyl group having at least one fluorine atom, R2 represents a C...  
WO/2008/109697A3
Compounds of Formula I, wherein Ar, L, m, R1, R2, R3, W, X, Y, Z are as defined in the claims, are described that are active on at least one of PPARα, PPARδ and PPARγ, which are useful for therapeutic and/or prophylactic methods invol...  
WO/2008/114275A3
The present invention provides novel anthranilic acid derivative useful as potential anticancer agent. More particularly, the present invention relates novel anthranilic acid derivative of general formula (8), R' = alkyl-2-methoxyphenyl ...  
WO/2008/107611A3
The invention concerns the use of at least one diol and/or at least one triol as an additive to dimethylsulfoxide (DMSO) in order to lower the crystallization point of same. The DMSO formulation is used in combination with the aforementi...  
WO/2008/133112A1
Disclosed is (1) a sulfone compound having a propargyl group. Also disclosed is (2) a nonaqueous electrolyte solution for lithium secondary batteries, which is obtained by dissolving an electrolyte in a nonaqueous solvent, which nonaqueo...  
WO/2008/123207A1
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...  
WO/2008/119176A1
This invention describes an amidation process whereby amino acids of the Formulae IIA or IIB can be activated and treated with an amine in the presence of a base to yield amides of the Formula (I), without loss of optical purity.  
WO/2008/114275A2
The present invention provides novel anthranilic acid derivative useful as potential anticancer agent. More particularly, the present invention relates novel anthranilic acid derivative of general formula (8), R' = alkyl-2-methoxyphenyl ...  
WO/2008/115999A1
This invention is directed to compounds of formula (I), wherein A, B, m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodr...  
WO/2008/111563A1
[PROBLEMS] To produce an optically active sulfoxide compound which is useful as an intermediate or a starting material for the synthesis of a physiologically active substance such as a pharmaceutical agent, at high optical purity. [MEANS...  
WO/2008/110308A2
Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.  
WO/2008/110621A1
The present invention relates to two crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoro-ethoxymethyl )benzoyl]cyclohexan-1,3-dione, which is also known under the common name tembotrione. The invention also relates to a ...  
WO/2008/108735A1
The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and d...  
WO/2008/109697A2
Compounds of Formula I, wherein Ar, L, m, R1, R2, R3, W, X, Y, Z are as defined in the claims, are described that are active on at least one of PPARα, PPARδ and PPARγ, which are useful for therapeutic and/or prophylactic methods invol...  
WO/2008/041140A3
This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositio...  
WO/2008/093711A1
Disclosed is a solid-phase oxidation reaction system for an organic compound, which has such advantages that the system does not require any organic solvent which may adversely affect the global environment, has a high product yield, ena...  
WO/2008/093506A1
Disclosed is a recording material composition which comprises a crosslinked diphenylsulfone compound and a monohydroxydiphenylsulfone derivative and is excellent in color-developing property and image storage stability. Specifically disc...  
WO/2008/078811A1
It is intended to provide a novel herbicide which has a wide range of applications to arable and non-arable lands and the like, and various methods for application to soil treatment, stem and leaf treatment and the like, and exhibits an ...  
WO/2008/078674A1
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...  
WO/2008/076256A1
The present invention discloses prodrugs of chloramphenicol, thiamphenicol and their analogs, as well as pharmaceutically acceptable salts thereof, including nitrogen-containing esters of both alcohol groups. These prodrugs have the Form...  
WO/2008/075672A1
Disclosed is a method for producing a tris(perfluoroalkanesulfonyl)methide acid salt represented by the formula [1], which comprises a step (a) for obtaining a reaction mixture by reacting a methyl magnesium halide represented by the for...  
WO/2008/074132A1
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...  
WO/2007/103221A3
The invention encompasses processes for preparing intermediates, such as (R)-modafinic acid and its C1-2 alkyl ester, and the conversion of the intermediates into armodafinil. In particular, the invention concerns: (i) a process for the ...  
WO/2007/069020A3
Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical c...  
WO/2007/127639A3
This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula (I) wherein (II) is a biologically-active moiety comp...  
WO/2008/027604A3
RF-compositions including surfactants, foam stabilizers, monomers, polymers, urethanes, intermediates, metal complexes, phosphate esters as well as telomerization methods are provided.  
WO/2008/070143A1
The present invention encompasses processes (1) for preparing racemic 2-(benzhydrylsulfinyl)acetic acid by combining the (S)- or the (R)-enantiomer with at least one organic solvent and at least one acid promoter, such as perchloric acid...  
WO/2007/098273A3
The invention encompasses crystalline forms of armodafinil , processes for preparing the crystalline forms, and pharmaceutical formulation.  
WO2006138508B1
Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particular...  
WO/2008/015139A3
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors...  
WO/2008/044033A1
The invention concerns amide compounds of Formula (I) wherein groups R1, R2, R3, Q1, X, R4, R5, R6, and R7 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmace...  
WO/2007/147771A3
Compounds of the formula (I), (II) or (III); or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods fo...  
WO/2008/041140A2
This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositio...  
WO/2008/037072A1
Compounds of formula ( I ) : are found to be selective inhibitors of cathepsin B, and hence useful in treating a variety of pathological conditions.  
WO/2008/009816A3
The invention relates to aromatic sulfinates and sulfonyl halides, and to the preparation thereof. The halides and the sulfinates are respectively of formulae Ar-Z- (CF2) n-CFRf-SO2Y (I) and [Ar-Z- (CF2) n-CFRf-SO2] m M wherein Z is a su...  
WO/2008/039645A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2008/039999A1
Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, c...  
WO/2004/066943A3
Encephalotoxin produced by activated mononuclear phagocytes is present in individuals having neurological disease including neurodegenerative and neuro-inflammatory diseases, such as Alzheimer's disease (AD), HIV-1-associated dementia (H...  
WO/2008/032453A1
Disclosed is a commercially advantageous method for producing a hydrazone represented by the formula (4) below. Specifically disclosed is a method for producing a hydrazone according to the following reaction formula.  
WO/2008/013791A3
Disclosed herein are compounds of formula (I) and formula (II), where R1-R4 are as defined in the claims, which are antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of.currently prescr...  
WO/2008/027604A2
RF-compositions including surfactants, foam stabilizers, monomers, polymers, urethanes, intermediates, metal complexes, phosphate esters as well as telomerization methods are provided.  
WO/2008/024746A1
Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.  
WO/2008/015139A2
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors...  

Matches 551 - 600 out of 10,857